Metis TechBio and Eli Lilly agree an AI-driven lipid nanoparticle collaboration worth up to about US$1.1 billion

Metis TechBio (a China-incorporated company listed in Hong Kong, stock code 7666) announced a strategic collaboration with Eli Lilly on tissue-specific lipid nanoparticle (LNP) delivery. Metis is eligible for an upfront payment in the low double-digit millions of US dollars, up to about US$1.1 billion in development, regulatory and commercial milestones, and single-digit tiered royalties; it will use its AI-driven ionizable lipid discovery platform AiLNP. Source is the company's voluntary announcement to the Hong Kong stock exchange dated 19 October 2026; terms are the company's own statement.